Cipla Lines Up Advair But Costs Will Flatten High-Value Launches
Higher R&D Costs And Market-Driven Inflation Expected In 2022/23
Executive Summary
A generic version of Advair is high on Cipla’s plans for its current financial year ending in March 2023. Management discussed the high-value respiratory asset and the company’s further prospects during the Indian firm’s annual earnings call, which included the company passing $1bn in sales for its domestic branded prescription business.
You may also be interested in...
Cipla Uncorks Peptide Injectables Pipeline
Cipla readies scale-up in peptide injectables with five filings in the US and gears for upcoming high-value launches for generic versions of Advair, Revlimid and Abraxane. The company is also exploring partnering opportunities for monkeypox.
Cipla Uncorks Peptide Injectables Pipeline, Eyes Partnering For Monkeypox
Cipla readies scale up in peptide injectables with five filings in the US and gears for upcoming high value launches for generic versions of Advair, Revlimid and Abraxane. The company is also exploring partnering opportunities for monkeypox.
Lupin Urged To ‘Put US In Order’ As It Slides To Annual Pre-Tax Loss
Lupin’s 2021/22 financial year results revealed weakness in its core US generics business amid challenging market conditions. The Indian firm will continue to throw its weight behind its domestic business while rebuilding the US operation with more complex, high-value launches.